U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H21N3O2S
Molecular Weight 295.4
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUMATRIPTAN

SMILES

CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1

InChI

InChIKey=KQKPFRSPSRPDEB-UHFFFAOYSA-N
InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C14H21N3O2S
Molecular Weight 295.4
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist indicated for acute treatment of migraine with or without aura in adults. Sumatriptan is structurally similar to serotonin (5-HT), and is a 5-HT receptor (types 5-HT1D and 5-HT1B) agonist. The specific receptor subtypes it activates are present on the cranial arteries and veins. Acting as an agonist at these receptors, sumatriptan reduces the vascular inflammation associated with migraines. The specific receptor subtype it activates is present in the cranial and basilar arteries. Activation of these receptors causes vasoconstriction of those dilated arteries. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. It is most effective taken early after the start of the pain. Injected sumatriptan is more effective than other formulations. Large doses of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to greenish-black, due to the integration of sulfur into the hemoglobin molecule. Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (V-Fib).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
330.0 nM [IC50]
38.3 nM [EC50]
35.0 nM [EC50]
5.3 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
IMITREX

Approved Use

Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1)

Launch Date

1997
Primary
IMITREX

Approved Use

Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1)

Launch Date

1997
Primary
IMITREX

Approved Use

Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1)

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
42 ng/mL
3 mg single, subcutaneous
dose: 3 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
77 ng/mL
3 mg single, intravenous
dose: 3 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
49 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
90 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
112 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
144 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
29 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
80 ng/mL
8 mg single, subcutaneous
dose: 8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 ng/mL
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
194 ng/mL
16 mg single, subcutaneous
dose: 16 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41 ng × h/mL
3 mg single, subcutaneous
dose: 3 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43 ng × h/mL
3 mg single, intravenous
dose: 3 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
158 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
380 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
44 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
476 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
590 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
83 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
105 ng × h/mL
8 mg single, subcutaneous
dose: 8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14 ng × h/mL
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
239 ng × h/mL
16 mg single, subcutaneous
dose: 16 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
3 mg single, subcutaneous
dose: 3 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.6 h
3 mg single, intravenous
dose: 3 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.1 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.5 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.4 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
83 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
8 mg single, subcutaneous
dose: 8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.1 h
16 mg single, subcutaneous
dose: 16 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / month multiple, oral
Dose: 200 mg, 1 times / month
Route: oral
Route: multiple
Dose: 200 mg, 1 times / month
Sources:
unhealthy, 18 - 65 years
n = 94
Health Status: unhealthy
Condition: acute migraine with aura
Age Group: 18 - 65 years
Sex: M+F
Population Size: 94
Sources:
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
(SUMATRIPTAN)
12 mg subcutaneous injections
Sources:
unhealthy, 35 years
n = 1
Health Status: unhealthy
Condition: migraine
Age Group: 35 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Sources:
6 mg 2 times / day multiple, subcutaneous
Overdose
Dose: 6 mg, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 6 mg, 2 times / day
Sources:
unhealthy, 36 years
n = 1
Health Status: unhealthy
Condition: episodic cluster headache
Age Group: 36 years
Sex: M
Population Size: 1
Sources:
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Other AEs: Abnormal physical sensation, Abnormal physical sensation...
Other AEs:
Abnormal physical sensation (6%)
Abnormal physical sensation (6%)
Abnormal physical sensation (6%)
Sensation of pressure (8%)
Chest tightness of (2%)
Throat tightness (3%)
Pain (1%)
Pressure (3%)
Vertigo (2%)
Malaise and fatigue (3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis 1 patient
Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
(SUMATRIPTAN)
12 mg subcutaneous injections
Sources:
unhealthy, 35 years
n = 1
Health Status: unhealthy
Condition: migraine
Age Group: 35 years
Sex: F
Population Size: 1
Sources:
Pain 1%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Chest tightness of 2%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Vertigo 2%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Malaise and fatigue 3%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Pressure 3%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Throat tightness 3%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Abnormal physical sensation 6%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Abnormal physical sensation 6%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Abnormal physical sensation 6%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Sensation of pressure 8%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
yes [IC50 6.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
weak (co-administration study)
Comment: coadministered with clarithromycin: mean sumatriptan AUC(infinity) and Cmax values after administration of combination treatment were 9% and 14% higher, respectively
yes
PubMed

PubMed

TitleDatePubMed
Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group.
1998 Nov-Dec
Fatal cardiac arrhythmia after oral sumatriptan.
1999 Jul-Aug
Dramatic headache relief after sumatriptan in a patient with a pituitary macroadenoma.
1999 Jun
Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
2000 Oct
Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.
2001
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.
2001
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
2001
New abortive agents for the treatment of migraine.
2001
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine.
2001 Apr
Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan.
2001 Apr
Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder.
2001 Apr
Cluster headache: review of the literature.
2001 Apr
[Current topics: expectation for new triptans].
2001 Apr 10
[Migraine: sumatriptan].
2001 Apr 10
[Migraine: selection of therapeutic agents to be applied during its attack].
2001 Apr 10
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients.
2001 Aug
Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis.
2001 Feb
Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets.
2001 Feb
Characterization of 5-HT receptors in the parasitic nematode, Ascaris suum.
2001 Feb
The impact of pharmacogenetics for migraine.
2001 Feb 9
Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan.
2001 Jan
Effect of sumatriptan on health care resource use among patients with migraine.
2001 Jan
pH-mediated field-amplified sample stacking of pharmaceutical cations in high-ionic strength samples.
2001 Jan
Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors.
2001 Jan
Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles.
2001 Jan
[First manifestation of migraine as acute confusional state: "confusional migraine" and diagnostic problems].
2001 Jan-Feb
Effect of rizatriptan in the spectrum of headache.
2001 Jun
Sumatriptan can alleviate headaches due to carotid artery dissection.
2001 Jun
[Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist].
2001 Jun
Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.
2001 Jun
Recent development in paediatric headache.
2001 Jun
Headache and female hormones: what you need to know.
2001 Jun
Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats.
2001 Jun 13
Gastric motor effects of triptans: open questions and future perspectives.
2001 Mar
Complicated migraine and migraine variants.
2001 Mar
Status migrainosus in children and adolescents.
2001 Mar
Headaches in children and adolescents: update 2001.
2001 Mar
Sumatriptin vs dihydroergotamine: patient preference.
2001 Mar
Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphé nuclei.
2001 Mar
Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers.
2001 Mar
Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs.
2001 Mar
The GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction: resemblance to the 5-HT(1B), but not to the 5-HT(1D) or 5-ht(1F), receptor subtype.
2001 Mar
Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation.
2001 Mar
Cardiovascular effects of SL65.0472, a 5-HT receptor antagonist.
2001 Mar 2
Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries.
2001 Mar 9
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.
2001 May
Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.
2001 May
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis.
2001 May
Oral almotriptan in the treatment of migraine: safety and tolerability.
2001 May
Neurogenic inflammation in the context of migraine.
2001 May 1
Patents

Sample Use Guides

Migraine Headache. Oral: 25 mg, 50 mg, or 100 mg PO (taken with fluids); Not to exceed 100 mg/dose; additional doses q2hr PRN. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hr; Not to exceed 12 mg SC q24hr Cluster Headache. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hour; Not to exceed 12 mg SC q24hr
Route of Administration: Other
The uptake of sumatriptan and other triptans via OCT1 and OCT3 was characterized using HEK293 cells stably transfected to overexpress wild-type OCT1 or OCT3. For measuring the uptake in human hepatocytes, was used cryopreserved human hepatocytes (Gibco Life Technologies, Darmstadt, Germany) obtained from a single donor with two fully active OCT1 alleles. Triptan uptake in OCT1 and OCT3-overexpressing HEK293 cells was measured by incubating the cells with varying concentrations of the substrates in 12-well plates for two minutes at pH 7.4 and 378C. The reaction was stopped with ice-cold buffer, the cells were lysed with 80% acetonitrile, and the intracellularly accumulated triptans were quantified by liquid chromatography coupled to tandem massspectrometry.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:42:42 GMT 2023
Edited
by admin
on Sat Dec 16 16:42:42 GMT 2023
Record UNII
8R78F6L9VO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUMATRIPTAN
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
DFN-11 (SUMATRIPTAN INJECTION)
Common Name English
DFN-11
Code English
IMITREX
Brand Name English
Sumatriptan [WHO-DD]
Common Name English
TOSYMRA
Brand Name English
SUMATRIPTAN [USP MONOGRAPH]
Common Name English
SUMATRIPTAN [MART.]
Common Name English
IMIGRAN
Brand Name English
SUMATRIPTAN [VANDF]
Common Name English
N02CC01
Code English
3-[2-(Dimethylamino)ethyl]-N-methy-1H-indole-5-methanesulfonamide
Common Name English
SUMATRIPTAN [HSDB]
Common Name English
SUMATRIPTAN [JAN]
Common Name English
SUMATRIPTAN [USP-RS]
Common Name English
SUMATRIPTAN [ORANGE BOOK]
Common Name English
SUMATRIPTAN [MI]
Common Name English
1H-INDOLE-5-METHANESULFONAMIDE, 3-(2-(DIMETHYLAMINO)ETHYL)-N-METHYL-
Systematic Name English
sumatriptan [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QN02CC01
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
NCI_THESAURUS C47794
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
NDF-RT N0000175763
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
LIVERTOX 916
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
NDF-RT N0000175764
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
NDF-RT N0000175765
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
WHO-ATC N02CC01
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
Code System Code Type Description
MERCK INDEX
m10396
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY Merck Index
DRUG CENTRAL
2543
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
MESH
D018170
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
NCI_THESAURUS
C1240
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
SMS_ID
100000091679
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
WIKIPEDIA
SUMATRIPTAN
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
CHEBI
64359
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
ChEMBL
CHEMBL128
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
INN
6125
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
CAS
103628-46-2
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
FDA UNII
8R78F6L9VO
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
EVMPD
SUB10770MIG
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
IUPHAR
54
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
EPA CompTox
DTXSID4023628
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
DAILYMED
8R78F6L9VO
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
RXCUI
37418
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY RxNorm
CHEBI
10650
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
RS_ITEM_NUM
1642154
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
PUBCHEM
5358
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
LACTMED
Sumatriptan
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
HSDB
7742
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
DRUG BANK
DB00669
Created by admin on Sat Dec 16 16:42:43 GMT 2023 , Edited by admin on Sat Dec 16 16:42:43 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE INACTIVE -> PARENT
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC